Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis
Authors:
- Giovanni FrancoGFGiovanni Franco
- Ibrahima BaIBIbrahima Ba
- Nadia NathanNNNadia Nathan
- Caroline KannengiesserCKCaroline Kannengiesser
- Antoine FroidureAFAntoine Froidure
- Effrosyni ManaliEMEffrosyni Manali
- Vincent BunelVBVincent Bunel
- Philippe BonniaudPBPhilippe Bonniaud
- Diane BouvryDBDiane Bouvry
- Marie Pierre DebrayMDMarie Pierre Debray
Open Access
- 26 March 2025
- journal article
- Published by Wiley in Respirology
- Vol. 30 (6) , 523-532
Abstract
Background and Objective: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD.Methods: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment.Results: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families.Conclusion: This study suggests that geneMDD could influence the treatment of FPF patients.Keywords
This publication has 44 references indexed in Scilit:
- Clinical Impact of Telomere Length Testing for Interstitial Lung DiseaseChest, 2024
- Lung Transplantation under a Janus Kinase Inhibitor in Three Patients with SAVI SyndromeJournal of Clinical Immunology, 2023
- Biologic characterization of ABCA3 variants in lung tissue from infants and children with ABCA3 deficiencyPediatric Pulmonology, 2022
- Familial Pulmonary FibrosisChest, 2021
- Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung DiseaseChest, 2021
- Lung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene VariantsChest, 2019
- Telomerase Variants in Patients with Cirrhosis Awaiting Liver TransplantationHepatology, 2019
- Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung DiseasesChest, 2018
- Severe hematologic complications after lung transplantation in patients with telomerase complex mutationsThe Journal of Heart and Lung Transplantation, 2015
- Constitutional telomerase mutations are genetic risk factors for cirrhosisHepatology, 2011